MEDICAL ASSISTANCE BULLETIN

Transcription

1 ISSUE DATE SUBJECT EFFECTIVE DATE January 20, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See Below BY Drug List (PDL) Update January 20, 2016 Pharmacy Services Leesa M. Allen, Deputy Secretary Office of Medical Assistance Programs IMPORTANT REMINDER: All providers (including all associated service locations - 13 digits) who enrolled on or before March 25, 2011 must revalidate their enrollment information no later than March 24, New enrollment application including all revalidation requirements may be found at Please send in your application(s) as soon as possible. PURPOSE: The purpose of this bulletin is to inform providers about updates to the Drug List (PDL), effective January 20, SCOPE: This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program and providing services in the fee-for-service (FFS) delivery system, including pharmacy services to residents of long term care facilities. BACKGROUND: The Department of Human Services (Department) Pharmacy and Therapeutics (P&T) Committee meets semi-annually to review published peer-reviewed clinical literature and make recommendations relating to new drugs in therapeutic classes already included in the PDL, changes in the status of drugs on the PDL from preferred to non-preferred and non-preferred to preferred, new quantity limits, and new classes of drugs to be added to or deleted from the PDL. The P&T Committee also recommends new guidelines or modifications to existing guidelines to evaluate requests for prior authorization of prescriptions for medical necessity. * COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO: The appropriate toll free number for your provider type Visit the Office of Medical Assistance Programs Web site at

2 2 DISCUSSION: The P&T Committee made the following recommendations during the most recent semiannual meeting in November 3, 2015, which were reviewed and approved by the Department. Classes of drugs subject to the PDL with no changes: Antidepressants, Other Antihypertensives, Sympatholytic Antipsoriatics, Oral Anxiolytics Botulinum Toxins Diabetic Meters & Strips Erythropoiesis Stimulating Proteins Histamine II Receptor Blockers Immunomodulators, Topical Iron, Parenteral Oncology Agents, Breast Cancer Ophthalmic Antibiotics Otic Anti-Infectives & Anesthetics Progestational Agents Low Thalidomide & Derivatives Classes of drugs added to the PDL: Idiopathic Pulmonary Fibrosis Agents Macular Degeneration Agents Methotrexate Classes of drugs or drugs removed from the PDL None PDL status of new drug classes, new drugs, drugs not previously reviewed, and drugs with a change in status Alzheimer s Agents Namzaric memantine tablet memantine tablet dose pack Anti-Allergens, Oral Oralair Anticonvulsants, Oral Tegretol tablet carbamazepine suspension carbamazepine tablet lamotrigine ODT oxcarbazepine suspension

3 3 Antidepressants, SSRIs fluoxetine 60 mg Antihistamines, Minimally Sedating fexofenadine suspension OTC Antihyperuricemics colchicine capsule colchicine tablet Antiparkinson s Rytary Agents pramipexole ER tolcapone Antipsoriatics, Dovonex cream Topical calcipotriene cream Antipsychotics Invega Trinza Rexulti aripiprazole tablet chlorpromazine Bile Salts Actigall Cholbam Urso/Urso Forte tablet ursodiol 300 mg capsule Bronchodilators, Beta Proair HFA Agonist Proair Respiclick Colony Stimulating Neulasta kit Factors Zarxio COPD Agents Incruse Ellipta Spiriva Respimat Stiolto Respimat Tudorza Pressair Cytokine and CAM Cosentyx pen Antagonists injector Cosentyx syringe Emollients Bionect HPR plus hydrogel Enzyme Replacement, Gauchers Disease Cerdelga Epinephrine, Self- Injected epinephrine (Adrenaclick) Glucocorticoids, Advair HFA Inhaled Aerospan Arnuity Ellipta Asmanex HFA

4 4 Glucocorticoids, Flovent Diskus Inhaled, continued Pulmicort Flexhaler budesonide 1 mg respules Glucocorticoids, Oral prednisolone sodium phosphate ODT Hepatitis C Agents Daklinza Harvoni Technivie Idiopathic Pulmonary Esbriet Fibrosis Agents Ofev Immunomodulators, Atopic Dermatitis tacrolimus Intranasal Rhinitis Astepro Agents Flonase OTC Qnasl 40 azelastine (Astelin) olopatadine Iron, Oral Fusion OTC feriva 21-7 feriva FA Leukotriene Modifiers zafirlukast Macular Eylea Degeneration Agents Lucentis Macugen Methotrexate Otrexup auto injector Rasuvo auto injector Rheumatrex tablet dose pack Trexall tablet methotrexate tablet methotrexate PF vial methotrexate vial Neuropathic Pain Irenka Agents duloxetine (Irenka) NSAIDs DermacinRx Lexitral Pennsaid pump Tivorbex celecoxib diclofenac potassium naproxen CR naproxen sodium

5 5 Oncology Agents, Farydak Oral Ibrance Lenvima Lynparza Temodar capecitabine temozolomide Ophthalmic Antibiotic-Steroid blephamide S.O.P. Combinations Ophthalmics for Allergic Conjunctivitis Pazeo Ophthalmics, Anti- Acular Inflammatories Iluvien Ophthalmics for Iopidine Glaucoma Timoptic apraclonidine bimatoprost 2.5 ml, 5 ml, and 7.5 ml Otic Antibiotic Ciprofloxacin Preparations ofloxacin Sedative Hypnotics Belsomra Smoking Cessation Nicorette lozenge OTC High Medium Very High DermacinRx Silapak Elocon solution Clobex lotion, shampoo and spray Temovate cream and ointment nicotine lozenge OTC fluocinonide cream, emollient, gel, ointment, and solution triamcinolone acetonide aerosol triamcinolone acetonide lotion fluocinolone acetonide cream, ointment, and solution fluticasone propionate cream and ointment hydrocortisone butyrate solution

6 6 clobetasol propionate cream, Very High, continued ointment, and spray Stimulants and Aptensio R Related Agents Evekeo Dexedrine tablet dexmethylphenidate guanfacine ER methylphenidate chewable tablets methylphenidate ER (Concerta, non-ab-rated) New Drugs that require clinical prior authorization: Cholbam Daklinza Eylea Farydak Harvoni Ibrance Lenvima Lucentis Lynparza Memantine tablet Memantine tablet dose pack Oralair Technivie PROCEDURE: The procedures for prescribers to request prior authorization of non-preferred drugs, preferred drugs that require prior authorization, and drugs not subject to the PDL that require prior authorization and for pharmacies to dispense an emergency supply of medication when necessary and without prior authorization are located In SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapters related to specific therapeutic classes of drugs) in reviewing the prior authorization request to determine medical necessity. The requirements for prior authorization and clinical review guidelines to determine medical necessity of non-preferred and preferred drugs listed above and updated handbook chapters will be published in separate MA Bulletins.

7 As set forth in 55 Pa. Code (a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs that require prior authorization. ATTACHMENTS: Prior Authorization of Pharmaceutical Services Handbook - Updated pages 7 SECTION I Providers can view the most recent PDL at: Providers can view the most recent Quantity Limits List at: NOTE: Providers may call , Option 1 to request a hard copy of the most recent PDL and Quantity Limits List SECTION II Table of Contents